Brilique
ticagrelor
Peripheral Vascular Diseases
Acute Coronary Syndrome
Date of authorisation:
Revision: 21
Last updated:
MedicineHumanAuthorised
EMEA-003146-PIP01-21 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: P/0113/2022
Route(s) of administration: Oral use
Pharmaceutical form(s):
Capsule (hard)
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-000480-PIP01-08-M14 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseasesHaematology-Hemostaseology
PIP number: P/0175/2021
Route(s) of administration: Oral use
Pharmaceutical form(s):
Film-coated tablet
Orodispersible tablet
Tablet
Decision date:
Last updated:
Compliance check: ✔
PIPHuman
Lumoxiti
moxetumomab pasudotox
Leukemia, Hairy Cell
Date of authorisation:
Last updated:
MedicineHumanWithdrawn
EMEA-002525-PIP01-18 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: P/0228/2019
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Powder for concentrate for solution for infusion
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Possia
ticagrelor
Peripheral Vascular Diseases
Acute Coronary Syndrome
Date of authorisation:
Revision: 2
Last updated:
MedicineHumanWithdrawn